[Clinical study of combination of Chinese medicine and western medicine in treatment of 500 patients with hemophilia hemorrhage]
- PMID: 21866655
[Clinical study of combination of Chinese medicine and western medicine in treatment of 500 patients with hemophilia hemorrhage]
Abstract
Objective: To study the effect and safety of haemostatic apozem combined with haemostatic mixture on hemophilia hemorrhage.
Methods: Five hundred hemophilia patients were randomly recruited from Shaanxi Yida Hematology Institute from February 2005 to July 2010. Under the condition of using no blood products such as platelet cofactors VIII and IX, oral administration of haemostatic apozem combined with intravenous dripping of haemostatic mixture were given to 332 hemorrhagic patients and 451 patients in need of surgery for hemorrhagic prevention. The treatment was lasted for three successive weeks. The hemostatic time, hemorrhage absorption (recovery) time, and their safety were observed.
Results: The hemostatic time for open bleeding and closed bleeding was (0.85 +/- 0.83) h and (2.69 +/- 0.65) h respectively. The average hemostatic time was (2.00 +/- 0.69) h. The recovery time for different portions was as follows respectively: intra-cranial hemorrhage (14.13 +/- 6.01) days; muscular hemorrhage (18.18 +/- 7.34) days; hematuria (8.25 +/- 4.69) days; arthrorrhagia(3.27 +/- 1.31) days; ecchymoma (7.16 +/- 2.32) days; bleeding of oral and nasal cavities (4.26 +/- 1.35) days; intramedullary hemorrhage (19.15 +/- 1.36) days; hematoma ulceration (50.01 +/- 20.91) days. The hemorrhage recovery ratio was 99.10% (329/332). The success rate of preventing from surgery hemorrhage was 100% (451/451). No severe adverse reaction occurred during the therapeutic course.
Conclusions: Haemostatic apozem combined with haemostatic mixture was effective and fast in preventing and treating hemophilia hemorrhage, with no complications or adverse reactions. It could be taken as the first choice for prevention and treatment of hemophilia hemorrhage.
Similar articles
-
Study on the efficacy and safety of Xueyou Mixture in treating hemophilia.Chin J Integr Med. 2007 Jun;13(2):141-4. doi: 10.1007/s11655-007-0141-6. Chin J Integr Med. 2007. PMID: 17609915 Clinical Trial.
-
Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.Haemophilia. 2015 Sep;21(5):e436-9. doi: 10.1111/hae.12737. Epub 2015 Jun 8. Haemophilia. 2015. PMID: 26058730 No abstract available.
-
Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.Thromb Res. 2011 Mar;127(3):247-53. doi: 10.1016/j.thromres.2010.11.030. Epub 2011 Jan 8. Thromb Res. 2011. PMID: 21220152
-
Current issues in prophylactic therapy for persons with hemophilia.Acta Haematol. 2006;115(3-4):162-71. doi: 10.1159/000090930. Acta Haematol. 2006. PMID: 16549891 Review.
-
Central venous access devices in patients with hemophilia.Expert Rev Med Devices. 2005 Nov;2(6):699-711. doi: 10.1586/17434440.2.6.699. Expert Rev Med Devices. 2005. PMID: 16293097 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical